Circulating tumor DNA analysis guides adjuvant therapy in colon cancer: An approach based on circulating tumor DNA for the treatment of stage II colon cancer reduced adjuvant chemotherapy use without compromising recurrence-free survival.
JAK inhibitor upadacitinib as induction and maintenance therapy for ulcerative colitis: In a phase 3 trial program, upadacitinib was superior to placebo to induce and maintain clinical remission in patients with moderately to severely active ulcerative colitis with a reasonable safety profile.
Current meta-analysis on discontinuation of nucleos(t)ide analogues (NA) in HBeAg-negative chronic hepatitis B: The current meta-analysis demonstrates that the "STOP-NUC" strategy is associated with clinical relapse in only approximately one third of patients and that the rate of HBsAg clearance increases with follow-up. With adequate monitoring to detect rare acute worsening, "STOP-NUC" is an important strategy towards functional cure of hepatitis B.
Mahmud N et al, Gastroenterology. 2022;163(1):257–69.e6
Recent study on benefits and risks of proton-pump inhibitors (PPI) in cirrhosis: A large national cohort study in the US Veterans Health Administration's health system confirms that PPI use is associated with an increased risk of infection and decompensation in cirrhosis. However, in patients with prior gastrointestinal bleeding, PPI use was associated with reduced all-cause mortality, suggesting a benefit of PPIs in the presence of an appropriate indication.
Meta-analysis on the benefit of surveillance for hepatocellular carcinoma (HCC) in patients with cirrhosis: The current study clearly demonstrates the benefit of HCC surveillance with regard to early diagnosis, curative treatment strategy, and survival.
Timing of endoscopy for acute non-variceal upper gastrointestinal bleeding: Results of a retrospective cohort study suggest that early endoscopy between 6 and 24 hours after admission results in better clinical outcomes as compared to urgent (< 6 h) or late endoscopy (24–48 h). These findings suggest that endoscopy should be performed within 24 hours after admission, but also emphasizes the importance of prior resuscitation and pharmacotherapy.
Over-the-scope-clips (OTSC) vs. standard treatment in high-risk patients with acute non-variceal upper gastrointestinal bleeding: OTSC therapy appears to be superior to standard treatment with clips when used by trained physicians for selected cases of primary therapy in patients with high risk of rebleeding.
Risankizumab as induction therapy for Crohn’s disease: The interleukin-23 antibody risankizumab was effective and safe as induction therapy in patients with moderately to severely active Crohn’s.
A fecal microbiota signature with high specificity for pancreatic cancer: Results of this translational study indicate that non-invasive, robust and specific fecal microbiota-based screening for the detection of pancreatic ductal adenocarcinoma is feasible.
Diagnosis and Therapy of Chronic Liver and Biliary Diseases
Author: J. Rasenack
(63 pages)
[cs_element_section _id=”1″ ][cs_element_layout_row _id=”2″ ][cs_element_layout_column _id=”3″ ][cs_element_text _id=”4″ ][cs_element_headline _id=”5″ ][cs_element_text _id=”6″ ][cs_element_text _id=”7″ ][cs_element_button _id=”8″ ][cs_element_video _id=”9″ ][cs_element_text _id=”10″ ][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id=”11″ ][cs_element_layout_column _id=”12″ ][cs_element_image _id=”13″ ][cs_element_text _id=”14″ ][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id=”15″ ][cs_element_layout_column _id=”16″ ][cs_element_text _id=”17″ ][cs_element_text _id=”18″ ][cs_element_headline _id=”19″ ][cs_element_button _id=”20″ ][/cs_element_layout_column][cs_element_layout_column _id=”21″ ][cs_element_text _id=”22″ ][cs_element_text _id=”23″ ][cs_element_headline _id=”24″ ][cs_element_button _id=”25″ ][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id=”26″ ][cs_element_layout_column _id=”27″ ][cs_element_image _id=”28″ ][cs_element_text _id=”29″ ][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id=”30″ ][cs_element_layout_column _id=”31″ ][cs_element_text _id=”32″ ][cs_element_text _id=”33″ ][cs_element_headline _id=”34″ ][cs_element_button _id=”35″ ][/cs_element_layout_column][cs_element_layout_column _id=”36″ ][cs_element_text _id=”37″ ][cs_element_text _id=”38″ ][cs_element_headline _id=”39″ ][cs_element_button _id=”40″ ][/cs_element_layout_column][cs_element_layout_column _id=”41″ ][cs_element_text _id=”42″ ][cs_element_text _id=”43″ ][cs_element_headline _id=”44″ ][cs_element_button _id=”45″ ][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id=”46″ ][cs_element_layout_column _id=”47″ ][cs_element_image _id=”48″ ][cs_element_text _id=”49″ ][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id=”50″ ][cs_element_layout_column _id=”51″ ][cs_element_text _id=”52″ ][cs_element_text _id=”53″ ][cs_element_headline _id=”54″ ]Timing of endoscopy for acute non-variceal upper gastrointestinal bleeding: Results of a retrospective cohort study suggest that early endoscopy between 6 and 24 hours after admission results in better clinical outcomes as compared to urgent (< 6 h) or late endoscopy (24–48 h). These findings suggest that endoscopy should be performed within 24 hours after admission, but also emphasizes the importance of prior resuscitation and pharmacotherapy.\n\n[/cs_content_seo][cs_element_button _id="55" ][cs_content_seo]Link to Falk Mediacenter\n\n[/cs_content_seo][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id="56" ][cs_element_layout_column _id="57" ][cs_element_text _id="58" ][cs_content_seo]Text:\n\n[/cs_content_seo][cs_element_text _id="59" ][cs_content_seo]Meier B et al, Gut. 2022;71(7):1251–8\n\n[/cs_content_seo][cs_element_headline _id="60" ][cs_content_seo]Over-the-scope-clips (OTSC) vs. standard treatment in high-risk patients with acute non-variceal upper gastrointestinal bleeding: OTSC therapy appears to be superior to standard treatment with clips when used by trained physicians for selected cases of primary therapy in patients with high risk of rebleeding.\n\n[/cs_content_seo][cs_element_button _id="61" ][cs_content_seo]Link to Falk Mediacenter\n\n[/cs_content_seo][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id="62" ][cs_element_layout_column _id="63" ][cs_element_text _id="64" ][cs_content_seo]Text:\n\n[/cs_content_seo][cs_element_text _id="65" ][cs_content_seo]D'Haens G et al, Lancet. 2022;399(10340):2015–30\n\n[/cs_content_seo][cs_element_headline _id="66" ][cs_content_seo]Risankizumab as induction therapy for Crohn’s disease: The interleukin-23 antibody risankizumab was effective and safe as induction therapy in patients with moderately to severely active Crohn’s.\n\n[/cs_content_seo][cs_element_button _id="67" ][cs_content_seo]Link to Falk Mediacenter\n\n[/cs_content_seo][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id="68" ][cs_element_layout_column _id="69" ][cs_element_image _id="70" ][cs_element_text _id="71" ][cs_content_seo]Pancreas\n\n[/cs_content_seo][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id="72" ][cs_element_layout_column _id="73" ][cs_element_text _id="74" ][cs_content_seo]Text:\n\n[/cs_content_seo][cs_element_text _id="75" ][cs_content_seo]Kartal E et al, Gut. 2022;71(7):1359–72\n\n[/cs_content_seo][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id="76" ][cs_element_layout_column _id="77" ][cs_element_headline _id="78" ][cs_content_seo]A fecal microbiota signature with high specificity for pancreatic cancer: Results of this translational study indicate that non-invasive, robust and specific fecal microbiota-based screening for the detection of pancreatic ductal adenocarcinoma is feasible.\n\n[/cs_content_seo][cs_element_button _id="79" ][cs_content_seo]Link to Falk Mediacenter\n\n[/cs_content_seo][cs_element_headline _id="80" ][cs_content_seo]Event\n\n[/cs_content_seo][cs_element_text _id="81" ][cs_content_seo]Symposium 230
State-of-the-Art Management of IBD: Current Realities and Future Horizons
November 25 – 26, 2022, Frankfurt, Germany
Kap Europa, Osloer Str. 5, 60327 Frankfurt, Germany\n\n[/cs_content_seo][cs_element_button _id="82" ][cs_content_seo]Program\n\n[/cs_content_seo][cs_element_button _id="83" ][cs_content_seo]Online registration\n\n[/cs_content_seo][/cs_element_layout_column][/cs_element_layout_row][cs_element_layout_row _id="84" ][cs_element_layout_column _id="85" ][cs_element_headline _id="86" ][cs_content_seo]Current Falk literature:\n\n[/cs_content_seo][cs_element_text _id="87" ][cs_content_seo]Diagnosis and Therapy of Chronic Liver and Biliary Diseases
Author: J. Rasenack
(63 pages)\n\n[/cs_content_seo][/cs_element_layout_column][/cs_element_layout_row][/cs_element_section][/cs_content]
